Urological infections due to multidrug-resistant bacteria: what we need to know?Breakthrough Cancer Pain: Preliminary Data of The Italian Oncologic Pain Multisetting Multicentric Survey (IOPS-MS)Safety profile of the fluoroquinolones: analysis of adverse drug reactions in relation to prescription data using four regional pharmacovigilance databases in Italy.Clinical pharmacokinetics of depot leuprorelin.New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance.Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy.A survey on infection management practices in Italian ICUsPharmacological properties of antifungal drugs with a focus on anidulafungin.Management of serious meticillin-resistant Staphylococcus aureus infections: what are the limits?Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression.The difficulties of polytherapy: examples from antimicrobial chemotherapy.Pharmacological aspects of the antibiotics used for urological diagnostic procedures.Treatment of extensively drug-resistant Gram-negative infections in critically ill patients: Outcome of a consensus meeting at the 13th Asia-Pacific Congress of Clinical Microbiology and Infection, October 2012.Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedules.Efficacy of caspofungin against Aspergillus terreus.Therapeutic recommendations of the multidisciplinary group.Concentration of moxifloxacin in plasma and tonsillar tissue after multiple administration in adult patients.[Pharmacodynamic and pharmacokinetic of antibiotics for treatment of skin and soft tissue infections].Gold(III) complexes with bipyridyl ligands: solution chemistry, cytotoxicity, and DNA binding properties.Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer.The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections.Ertapenem peritoneal fluid concentrations in adult surgical patients.Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis.[Pharmacological rationale for choice of antibiotics for intraabdominal infections].Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers.Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections.Factors Influencing the Clinical Presentation of Breakthrough Pain in Cancer Patients.Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil
P50
Q30376593-A7A19C53-83E6-40B8-A30E-93AD3C09E8D2Q31143906-0C18C555-E388-4D9E-96C8-F4E552D096F1Q33654583-A1E59CD4-070B-45A3-BA11-86769D4B6431Q34135364-64703972-2307-40E3-8EE4-676DE5DBC209Q34242777-14C27B28-E8F1-430D-B93C-01DEF304C2ACQ34782587-709A53AA-B331-438A-ACDA-88AF932F656AQ36902763-4999231D-F5E9-4610-B0D9-692448325986Q37624716-4BCAD832-C10C-47B0-8735-E8C121E3F628Q37837241-5B2CD05D-7D2C-40D9-A019-3167DF03604AQ37849716-F2311FB4-0F83-4814-8A85-2B35EA27A570Q37947161-5A16766B-F144-4BAB-8634-8AA8ADA92EBBQ38253258-7616983D-69DD-4089-B4E2-025B84A845D7Q39016447-F03D47FE-7B63-4835-94A1-5378DD6825ADQ40240920-063AA8AB-67A3-4EB7-8B73-DE8BF21DF0E3Q40668303-154C77E0-2863-4242-AEDA-DD4E4368401EQ41729769-BE527CD0-05CD-4A21-80D0-115562A29C8DQ42681408-AA114C78-6AE7-4B79-A749-3E39D63AC59BQ43081411-4C04ADC8-7DE0-4472-9051-2F3401FEB0B7Q43946320-D8525802-2C52-450A-AE58-FBB585EEADCCQ43950442-E2CA7FD3-6782-4670-8F2B-4BF3FDE93048Q45977952-8CFEFEA7-068E-466A-8961-D3B8746AA778Q46189699-349C026D-4359-4FFD-9B9A-5BD0CDC97316Q46472365-02EC8711-C820-414E-BC35-E122E02AA78EQ46669548-6B12D573-B1D3-43ED-9691-66AACFCC0664Q46718880-B2A8DCBD-5CD0-4E7C-9AAC-CAC5F7E046DAQ46869415-B6BAD0AC-3338-4735-AC8C-F3FC40DEBFF7Q54460259-2F3BEF3E-474B-48F3-BEA3-CC57BBBECF76Q55500110-CA93A9A6-EEE5-4DDC-9320-3CDD7CE25AA7Q57737846-9FDCB6C6-AB9F-4C5C-BE61-D5E0EB4CE1E1
P50
description
Forscher
@de
chercheur
@fr
hulumtuese
@sq
investigador
@es
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
研究者
@zh
name
Teresita Mazzei
@ast
Teresita Mazzei
@de
Teresita Mazzei
@en
Teresita Mazzei
@eo
Teresita Mazzei
@es
Teresita Mazzei
@fr
Teresita Mazzei
@it
Teresita Mazzei
@nl
Teresita Mazzei
@pt
Teresita Mazzei
@sv
type
label
Teresita Mazzei
@ast
Teresita Mazzei
@de
Teresita Mazzei
@en
Teresita Mazzei
@eo
Teresita Mazzei
@es
Teresita Mazzei
@fr
Teresita Mazzei
@it
Teresita Mazzei
@nl
Teresita Mazzei
@pt
Teresita Mazzei
@sv
prefLabel
Teresita Mazzei
@ast
Teresita Mazzei
@de
Teresita Mazzei
@en
Teresita Mazzei
@eo
Teresita Mazzei
@es
Teresita Mazzei
@fr
Teresita Mazzei
@it
Teresita Mazzei
@nl
Teresita Mazzei
@pt
Teresita Mazzei
@sv
P1153
7006078355
P18
P21
P31
P373
Teresita Mazzei
P496
0000-0002-5097-102X